Interpace Diagnostics (IDXG) is a fully integrated commercial and bioinformatics company that provides molecular and diagnostic tests as well as pathology services to evaluate the risk of cancer by leveraging the latest technology in personalized medicine for better informed clinical decisions and improved patient management. With the addition of their new lung assay, RespriDX, they now have 4 commercial diagnostic tests on the market and 1 product in the clinical evaluation process (CEP).
ThyGenX is their next-generation sequencing test for cancer risk assessment of thyroid nodules that improves preoperative diagnostic accuracy by providing physicians with greater confidence to rule-in cancer for indeterminate thyroid nodules. ThyraMIR is the first microRNA gene expression classifier for additional insight in the thyroid nodule biology. When ThyraMIR is used in combination with ThyGenX, these 2 tests enable physicians to more accurately identify and rule out thyroid cancer with a single testing service. PancraGEN is the first and only US commercially available molecular test for evaluation of pancreatic cysts. PancraGEN has the specificity required in a molecular diagnostics test to avoid many unnecessary surgeries. Their fourth test, RespriDX compares the genomic fingerprint of one lung tumor to that of a second lung tumor using a panel of 25 DNA markers with the intent of characterizing a nodule as either metastatic or new primary carcinoma. Finally, BarreGen for Barrett’s Esophagus is currently being soft launched with key opinion leaders (KOLs) as they continue to gather data on this assay. Barrett’s Esophagus is a rapidly growing diagnosis that affects >3M people in the US and can progress to esophageal cancer.